CytoDyn Inc. IPO Filing Research

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

First tracked pre-IPO filing for this issuer.

Common Stock · Ticker CYDY · Use of proceeds debt repayment and working capital

CytoDyn Inc. has filed an S-1 registration statement for its IPO, transitioning from a previous 424B3 prospectus supplement. The filing includes updated financial data as of February 28, 2026, with a focus on convertible notes, accrued liabilities, and operating losses. The company remains in a development stage, with significant accumulated deficits and ongoing legal and financial risks.

2026-04-22 · 0001104659-26-046921

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

375,999,668 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders, with no proceeds to the company.

The current filing updates the prospectus with financial results from CytoDyn Inc.'s quarterly report (10-Q) for the period ended February 28, 2026, and includes revised financial data, stock price information, and details about extended convertible note maturities. The filing emphasizes ongoing risks related to the company's financial position and reliance on convertible debt.

2026-04-08 · 0001104659-26-041012

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

375,999,668 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders, with no issuer proceeds

The current filing updates the prospectus to reflect amendments related to the extension of maturity dates for two secured convertible promissory notes (Note 1 and Note 2) by 36 months, a reduced annual interest rate of 5%, and a new monthly share payment structure to noteholders. The filing also incorporates recent disclosures from the Company's Form 8-K dated March 24, 2026, regarding these debt modifications.

2026-03-25 · 0001104659-26-034605

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

375,999,668 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants to purchase common stock at $0.26 per share, 5-year term, exercisable upon issuance · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the company · Underwriters Placement Agent

CytoDyn Inc. updated its prospectus supplement to reflect recent private placements, direct sales, and convertible note exchanges. The filing incorporates details from a Form 8-K dated March 5, 2026, including a private offering of 81.4 million units (common stock and warrants) raising $17.5 million, direct investments from accredited investors, a Standby Equity Purchase Agreement (SEPA) with Yorkville, and convertible note exchanges. The company also disclosed financial losses, accrued liabilities, and ongoing risks related to its operations and liquidity.

2026-03-09 · 0001104659-26-025325

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

375,999,668 shares

Common · Exchange OTCQB · Ticker CYDY · Warrants exercisable for 194,675,569 shares of common stock · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the company

CytoDyn Inc. updated its prospectus with information from its Q3 2025 10-Q filing, including consolidated financial statements and operational results. The filing emphasizes ongoing liquidity challenges, with cash reserves declining to $4.98M as of November 30, 2025, and a growing accumulated deficit of $915.93M. The company continues to rely on convertible notes and warrants for capital, while disclosing significant operating losses and risks related to its financial position and ability to continue as a going concern.

2026-01-09 · 0001104659-26-002535

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

375,999,668 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 194,675,569 shares of common stock underlying warrants · Selling stockholders only · Use of proceeds Proceeds from exercised warrants, if any

CytoDyn Inc. is registering up to 375,999,668 shares of common stock and underlying warrants for resale by selling stockholders under a prospectus. The company will not receive proceeds from the resale but may benefit from warrant exercises. The filing highlights ongoing financial challenges, including an accumulated deficit of $887.8 million as of May 2025, and risks related to its ability to continue as a going concern, regulatory approvals, and reliance on external capital.

2025-12-22 · 0001104659-25-123826

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for a POS AM submission on December 16, 2025, following an earlier S-3 filing on December 2, 2025. The current filing confirms the effectiveness of a securities registration statement, though no substantive details about business operations, financials, or offerings are provided in the text.

2025-12-16 · 9999999995-25-003778

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

120,000,000 shares

Common Stock, $0.001 par value · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds No issuer proceeds; selling stockholder's proceeds not specified · Flags cayman_holding_company · Underwriters YA II PN, Ltd.

CytoDyn Inc. filed a 424B3 registration statement for up to 120,000,000 shares of common stock offered by YA II PN, Ltd., a Cayman Islands exempt limited partnership. The shares are sold under a Standby Equity Purchase Agreement with YA, which will purchase shares at 98% of the lowest 3-day VWAP. The company will not receive proceeds from the selling stockholder but may receive up to $30 million from future Advance Shares. The filing emphasizes the Selling Stockholder's role as an underwriter and outlines pricing mechanisms and distribution terms.

2025-12-02 · 0001104659-25-117781

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. has filed a Form S-3 registration statement to allow the sale of up to 120 million shares of common stock by YA II PN, Ltd., a Cayman Islands exempt limited partnership. The offering is structured under a Standby Equity Purchase Agreement with YA, enabling the sale of shares at 98% of the lowest daily volume-weighted average price (VWAP) over a three-day period. CytoDyn will not receive proceeds from the sale but may receive up to $30 million in aggregate gross proceeds from sales to YA under the agreement. The company’s common stock is quoted on the OTCQB tier under the symbol 'CYDY.'

2025-12-02 · 9999999995-25-003478

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Gross proceeds $100,000,000

Common Stock, Warrants, Subscription Rights, Units · Exchange OTCQB · Ticker CYDY · Warrants may be convertible into common stock.

CytoDyn Inc. has filed a 424B3 prospectus supplement to register up to $100 million in common stock, warrants, subscription rights, and units. The filing outlines potential future offerings of these securities, which may be sold directly, through agents, underwriters, or dealers. The company's common stock is listed on the OTCQB under 'CYDY,' with a recent closing price of $0.29. The prospectus emphasizes that specific terms of offerings will be detailed in supplements, and investors should review the 'Risk Factors' section before investing.

2025-09-29 · 0001104659-25-094541

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its Form S-3 registration statement, effective August 21, 2025, allowing the resale of up to 279,236,439 shares of common stock and 207,410,284 shares underlying warrants by selling stockholders. The filing updates previous disclosures, incorporating information from a May 16, 2025, Form 8-K regarding changes in the company's independent auditor.

2025-08-21 · 9999999995-25-002703

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

486,646,723 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants exercisable for 207,410,284 shares of common stock · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the company

The current filing updates the prospectus supplement for CytoDyn Inc.'s share resale offering, incorporating changes from the May 16, 2025, Form 8-K. Key updates include the resignation of Marcum LLP as the independent auditor and engagement of CBIZ CPAs P.C., effective May 14, 2025. The filing also reaffirms the company's OTCQB trading status and risk disclosures from the original prospectus.

2025-05-16 · 0001558370-25-007955

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

486,646,723 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 207,410,284 shares of common stock underlying warrants · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders

The current 424B3 filing updates the prospectus for CytoDyn Inc., reflecting the appointment of Robert E. Hoffman as Chief Financial Officer (CFO) effective May 15, 2025, and incorporating financial data from the company's April 2025 10-Q. The filing also notes the resignation of the previous interim CFO, Mr. Cohen, effective May 12, 2025. The prospectus supplement relates to the resale of up to 486,646,723 shares of common stock and underlying warrants by selling stockholders.

2025-05-06 · 0001558370-25-006533

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

486,646,723 shares

Shares of Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds from the resale of shares by selling stockholders, with no proceeds going to the issuer

CytoDyn Inc. updated its prospectus with financial data from its Q1 2025 10-Q filing, reflecting changes in liquidity, operating losses, and share capital. The filing relates to the resale of up to 486,646,723 shares of common stock and underlying warrants by selling stockholders. The company reported a stock price of $0.20 as of April 14, 2025, with significant increases in cash reserves and liabilities compared to prior periods.

2025-04-15 · 0001558370-25-004849

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

486,646,723 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 207,410,284 shares of common stock underlying warrants · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders, with no proceeds to the company

The current 424B3 filing updates the prospectus for CytoDyn Inc. to include financial information from the company's Quarterly Report on Form 10-Q for the period ended November 30, 2024. The filing relates to the resale of up to 486,646,723 shares of common stock and underlying warrants by selling stockholders. The company's common stock is quoted on the OTCQB with a closing price of $0.15 as of January 13, 2025. Investors are cautioned to review the risk factors outlined in the prospectus.

2025-01-14 · 0001558370-25-000208

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

486,646,723 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 207,410,284 shares of common stock underlying warrants · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders, with no proceeds to the company

CytoDyn Inc. filed a 424B3 prospectus supplement to update its previously effective S-1 registration statement, incorporating information from its October 15, 2024, 10-Q filing. The supplement relates to the resale of up to 486,646,723 shares of common stock and underlying warrants by selling stockholders, with the company's stock currently trading on OTCQB at $0.14 per share as of October 16, 2024. The filing emphasizes risks associated with investing in the company's securities, referencing its Risk Factors section.

2024-10-17 · 0001558370-24-013379

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

486,646,723 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Shares underlying warrants · Selling stockholders only · Use of proceeds Proceeds from exercised warrants

CytoDyn Inc. filed a 424B3 prospectus for the resale of up to 486,646,723 shares of common stock and underlying warrants by selling stockholders. The company does not receive proceeds from the resale but may benefit from exercised warrants. The filing highlights ongoing financial challenges, including a net loss of $70 million in FY2023 and an accumulated deficit of $832 million, raising substantial doubt about its ability to continue as a going concern. The prospectus also notes unresolved commitments with Samsung BioLogics, which could result in future liabilities.

2024-10-01 · 0001558370-24-013117

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. has received effectiveness for its S-1 registration statement, enabling the resale of up to 486,646,723 shares of common stock by selling stockholders. The company is not directly selling shares or receiving proceeds from the resale, but may receive proceeds from warrant exercises. The filing includes updated financial statements as of May 31, 2024, and highlights ongoing audit concerns about the company's ability to continue as a going concern.

2024-10-01 · 9999999995-24-003058

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

CytoDyn Inc. has received SEC approval for its IPO registration statement, effective September 12, 2024. The filing confirms the company's readiness to proceed with its initial public offering, though specific details about the offering terms, pricing, or share structure are not explicitly outlined in the provided text.

2024-09-12 · 9999999995-24-002805

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received SEC approval for its IPO filing, effective September 12, 2024. The filing represents a revised submission compared to the previous version, with updates to regulatory identifiers.

2024-09-12 · 9999999995-24-002807

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Exchange NASDAQ · Ticker CYDY · Warrants issued in prior placements · Use of proceeds General corporate purposes · Flags warrants, units

CytoDyn Inc.'s current S-1 filing updates its prospectus with recent developments, including a change in independent auditors to Marcum LLP and details of a $12 million settlement with former CRO Amarex Clinical Research. The filing also references ongoing financial challenges, reliance on leronlimab, and risks related to clinical trial outcomes and regulatory approvals.

2024-09-09 · 0001558370-24-012660

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

141,019,099 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Includes 105,226,752 shares underlying warrants · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the issuer

The current filing updates the prospectus with information from Form 8-Ks dated June 28, 2024, and July 9, 2024. Key updates include the appointment of Marcum LLP as the independent accountant, a settlement with Amarex Clinical Research, LLC involving $12 million in payments, and the resale of up to 141,019,099 shares of common stock by selling stockholders. The filing also references ongoing risks outlined in the Prospectus and subsequent 10-Qs.

2024-07-09 · 0001558370-24-009721

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Resale of shares by selling stockholders

CytoDyn Inc.'s current 424B3 filing updates the prospectus to include information from Form 8-Ks dated June 28, 2024, and July 9, 2024. Key updates include the appointment of Marcum LLP as the independent auditor and a settlement agreement with Amarex Clinical Research LLC resolving a lawsuit. The filing also references the resale of up to 205,652,848 shares of common stock and warrants by selling stockholders, with the company's stock quoted on the OTCQB under 'CYDY.'

2024-07-09 · 0001558370-24-009722

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

141,019,099 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants to purchase 105,226,752 shares of common stock · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders

CytoDyn Inc. filed a prospectus supplement (424B3) dated May 6, 2024, updating its registration statement to include information from its Form 8-K reporting the dismissal of BF Borgers CPA PC as its independent auditor. The company's common stock remains quoted on the OTCQB under 'CYDY,' with a closing price of $0.147 per share as of May 3, 2024. The supplement relates to the resale of up to 141,019,099 shares of common stock and underlying warrants by selling stockholders.

2024-05-06 · 0001558370-24-006815

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

74,903,789 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders, with no proceeds to the company

The current filing updates the prospectus to reflect the dismissal of BF Borgers CPA PC as CytoDyn Inc.'s independent registered public accounting firm, following an SEC order barring the firm from appearing before the SEC. The company is transitioning to a new auditor for the fiscal year ending May 31, 2024. The filing also reaffirms the resale of up to 205,652,848 shares of common stock and warrants by selling stockholders, with no material changes to the offering structure compared to previous disclosures.

2024-05-06 · 0001558370-24-006816

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock, $0.001 par value · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds from the resale will be received by the selling stockholders, with no proceeds to the company.

The current filing updates the prospectus with information from CytoDyn Inc.'s 2024 Third Quarter 10-Q, including financial statements and management discussion. It relates to the resale of up to 205,652,848 shares of common stock and warrants by selling stockholders. The filing highlights the company's financial position, including operating losses and contingent liabilities, and references risk factors from the prospectus and 10-Q.

2024-04-16 · 0001558370-24-005207

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

141,019,099 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 105,226,752 shares underlying certain warrants · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds

CytoDyn Inc. filed a prospectus supplement (424B3) updating its registration statement with financial results from its Q3 2024 10-Q. The filing relates to the resale of up to 141,019,099 shares of common stock and underlying warrants by selling stockholders. The company reported a net loss of $11.9 million for the three months ended February 29, 2024, with significant operating and interest expenses. The prospectus highlights risks including financial instability, reliance on convertible notes, and market risks.

2024-04-16 · 0001558370-24-005208

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

141,019,099 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders, with no proceeds to the issuer.

CytoDyn Inc. filed a prospectus supplement (424B3) updating its registration statement for the resale of up to 141,019,099 shares of common stock. The supplement incorporates a Form 8-K dated April 8, 2024, detailing a restructuring of the company's obligations to Samsung BioLogics Co., Ltd., including a restructured Total Balance of $43,821,231.32 contingent on achieving qualifying revenue events. The company also outlines a wind-down process for services previously provided by Samsung.

2024-04-08 · 0001558370-24-004844

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 130,749,059 shares of common stock underlying warrants · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders, with no proceeds to the company

CytoDyn Inc. updated its prospectus supplement to reflect a Letter Agreement with Samsung BioLogics Co., Ltd., restructuring the Total Balance of $43,821,231.32. The agreement outlines contingent payments based on the company's qualifying revenue, with 20% of annual revenue applied toward repayment. The company also details a wind-down process for services previously provided by Samsung, including shipment or destruction of drug product and reference standards. The filing emphasizes the company's current inventory sufficiency for clinical activities and transition to alternative service providers.

2024-04-08 · 0001558370-24-004845

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only

CytoDyn Inc. updated its prospectus supplement to reflect the FDA lifting the clinical hold on leronlimab, enabling further development as an inflammation therapy. The filing also updates share details, noting the resale of up to 205,652,848 shares by selling stockholders, and includes the company's OTCQB stock price of $0.2575 as of February 29, 2024.

2024-03-01 · 0001558370-24-002274

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

141,019,099 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders

CytoDyn Inc. updated its prospectus supplement to reflect the lifting of the FDA's clinical hold on leronlimab, enabling further development as a therapy for chronic inflammation. The company plans to conduct an inflammation study to establish leronlimab's mechanism of action cost-effectively. The filing also updates the number of shares offered and references the latest prospectus dated February 22, 2024.

2024-03-01 · 0001558370-24-002275

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

141,019,099 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 105,226,752 shares of common stock underlying warrants · Selling stockholders only · Use of proceeds Proceeds from exercised warrants will be used for general corporate purposes

CytoDyn Inc. filed a 424B3 prospectus for the resale of up to 141,019,099 shares of common stock and underlying warrants by selling stockholders. The company does not receive proceeds from the resale but will benefit from warrant exercises. The filing relates to registration rights granted to selling stockholders, with shares listed on OTCQB under 'CYDY.' The prospectus highlights risks associated with convertible notes, default provisions, and financial obligations.

2024-02-22 · 0001558370-24-001547

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its S-1 registration statement on February 21, 2024, confirming the SEC has accepted the filing. The document primarily contains technical data points related to financial disclosures, stock awards, and legal entities, with no explicit details on business operations, financial performance, or offering terms.

2024-02-21 · 9999999995-24-000513

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Range $0.10 to $0.31 · 1,750,000,000 shares

Class A · Exchange NASDAQ · Ticker CYDY · Warrants issued to private placement agents · Use of proceeds Working capital and general corporate purposes

CytoDyn Inc. filed an S-1 registration statement for an IPO, detailing its financials, share structure, and corporate changes. The filing includes updates on leadership, including the appointment of Dr. Jacob P. Lalezari as CEO and Mitchell Cohen as Interim CFO, following the resignation of the previous CFO. The company also references prior prospectus supplements and updates to its capital structure, including stock options, warrants, and accrued liabilities.

2024-02-07 · 0001558370-24-000836

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 130,749,059 shares of common stock underlying certain warrants · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders, with no proceeds to the issuer

CytoDyn Inc. filed a prospectus supplement (424B3) updating its registration statement to include information from its January 29, 2024 Form 8-K. The filing relates to the resale of up to 205,652,848 shares of common stock and underlying warrants by selling stockholders. The supplement highlights executive changes, including Dr. Jacob P. Lalezari as CEO and Mitchell Cohen as Interim CFO, and notes Antonio Migliarese's resignation as CFO. The company's common stock is quoted on OTCQB under 'CYDY,' with a closing price of $0.16 as of January 26, 2024.

2024-01-29 · 0001558370-24-000626

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 130,749,059 shares of common stock underlying certain warrants · Selling stockholders only · Use of proceeds Selling stockholders reselling shares; no proceeds to the issuer · Flags warrants

The current filing updates the prospectus with financial results from CytoDyn Inc.'s 2024 Second Quarter 10-Q (ended November 30, 2023) and includes disclosures about the company's financial condition, operational losses, and ongoing regulatory challenges. The filing highlights the company's liquidity concerns, significant operating losses, and the impact of the FDA's clinical hold on its HIV trial protocol. It also references previous disclosures about the interim CEO's webcast update regarding FDA communications.

2024-01-19 · 0001558370-24-000387

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Resale of shares by selling stockholders with no issuer proceeds

CytoDyn Inc.'s current 424B3 filing updates the prospectus with information from its December 14, 2023, Form 8-K. The filing highlights the lifting of a partial clinical hold by the FDA but notes a new full hold due to unresolved comments on a proposed clinical trial protocol. The company plans to submit an amended protocol in January 2024. The filing also reflects an updated stock price of $0.20 as of December 14, 2023, compared to $0.18 in the previous filing.

2023-12-15 · 0001104659-23-126211

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 130,749,059 shares of common stock underlying certain warrants · Selling stockholders only · Use of proceeds Proceeds will be received by selling stockholders

CytoDyn Inc. filed a prospectus supplement (424B3) updating its registration statement for the resale of up to 205,652,848 shares of common stock. The supplement incorporates a Form 8-K dated November 28, 2023, which details the termination of the Master Services Agreement with Samsung BioLogics, effective January 5, 2024. The company states it has sufficient leronlimab for short-term clinical trials and is resolving outstanding issues with Samsung, including payment schedules and manufacturing delays. The filing also references ongoing risks related to reliance on third-party manufacturers and financial obligations.

2023-11-28 · 0001104659-23-121686

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will be used for general corporate purposes by the selling stockholders

CytoDyn Inc. filed a prospectus supplement (424B3) updating information related to its securities offering, including the appointment of Dr. Jacob P. Lalezari as interim CEO and changes to executive roles. The filing incorporates a Form 8-K dated November 21, 2023, which details the employment agreement with Dr. Lalezari and the cessation of Antonio Migliarese's interim President role. The supplement also references the company's OTCQB listing and risk factors outlined in the prospectus.

2023-11-22 · 0001104659-23-120646

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will be received by the selling stockholders

CytoDyn Inc. filed a prospectus supplement (424B3) on November 13, 2023, updating its registration statement to include information from a Form 8-K dated November 9, 2023. The update includes shareholder approvals for increasing authorized common stock from 1.35B to 1.75B shares, director elections, and an advisory vote on executive compensation. The company’s common stock is quoted on OTCQB under CYDY, with a closing price of $0.16 as of November 9, 2023.

2023-11-13 · 0001104659-23-117336

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

205,652,848 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholders, with no proceeds to the company

The current filing updates the prospectus for CytoDyn Inc.'s resale of up to 205,652,848 shares of common stock and underlying warrants by selling stockholders. It incorporates the company's Quarterly Report on Form 10-Q for the period ended August 31, 2023, and includes updated financial statements, risk factors, and operational details. The filing emphasizes risks related to financial stability, reliance on convertible notes, and market conditions.

2023-10-24 · 0001104659-23-110899

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

205,652,848 shares

common · Exchange OTCQB · Ticker CYDY · 130,749,059 shares of our common stock underlying certain warrants · Selling stockholders only · Use of proceeds Proceeds from warrant exercises

CytoDyn Inc. filed a 424B3 prospectus for the resale of up to 205,652,848 shares of common stock and underlying warrants by selling stockholders. The company is not issuing shares or receiving proceeds from the resale, but may receive proceeds from warrant exercises. The filing outlines the plan of distribution and references risk factors, with the stock quoted on OTCQB under 'CYDY.'

2023-10-11 · 0001104659-23-108379

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

The SEC has declared the registration of CytoDyn Inc.'s securities effective, allowing selling stockholders to resell up to 205,761,543 shares of common stock and underlying warrants. The company is not participating in the offering and will not receive proceeds from the resale, though it may benefit from warrant exercises. The stock is quoted on OTCQB under 'CYDY' with a recent closing price of $0.26 per share.

2023-10-05 · 9999999995-23-002938

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

205,761,543 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 133,749,059 shares underlying warrants · Selling stockholders only · Use of proceeds No proceeds to the issuer; selling stockholders bear all costs

CytoDyn Inc. filed a 424B3 prospectus for the resale of up to 205,761,543 shares of common stock and underlying warrants by selling stockholders. The company is not directly selling shares or receiving proceeds from their sale, but will benefit from cash exercises of warrants. The filing highlights risks associated with investing in the company's securities and notes the stock's OTCQB listing.

2023-07-11 · 0001104659-23-080035

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

The SEC has declared the S-1 registration statement for CytoDyn Inc. effective, allowing the company to proceed with its IPO. The filing confirms the acceptance of the offering, though specific details about the offering terms, use of proceeds, or financials are not included in the provided text.

2023-07-10 · 9999999995-23-002040

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $0.31 · Range $0.30 to $0.31 · 8,995,000 shares · Gross proceeds $1,350,000,000

Class A · Exchange NASDAQ · Ticker CYDY · Over-allotment 9,000 · Public and private warrants issued in separate offerings · Use of proceeds Working capital and general corporate purposes · Flags warrants

CytoDyn Inc. filed an S-1 registration statement, indicating preparation for an initial public offering (IPO). The filing includes details on previous private placements, warrant exchanges, and financial metrics. Key activities include stock issuances, litigation settlements, and executive changes. The company also references research and development agreements and intellectual property holdings.

2023-06-21 · 0001104659-23-073406

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc.'s registration statement became effective on February 9, 2023, following a delay from the previously scheduled September 30, 2022, effectiveness date. The filing type changed from S-3 to EFFECT, indicating final approval.

2023-02-09 · 9999999995-23-000336

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The Notice of Effectiveness indicates that the registration statement for CytoDyn Inc. has become effective as of February 9, 2023. This filing confirms the SEC's approval of the securities offering.

2023-02-09 · 9999999995-23-000337

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its IPO on February 9, 2023, under Form POS AM. The filing includes updated registration details compared to the previous submission.

2023-02-09 · 9999999995-23-000338

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received SEC effectiveness for its registration statement on February 9, 2023. The filing relates to a prior securities offering, with no visible textual content detailing operational, financial, or strategic updates in the provided documents.

2023-02-09 · 9999999995-23-000339

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received effectiveness for its registration statement on February 9, 2023, with a revised filing (POS AM) compared to the previous submission. The current filing confirms the registration of securities under the same form type as the prior notice, with updated technical identifiers.

2023-02-09 · 9999999995-23-000340

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received SEC effectiveness for a Post-Effective Amendment (POS AM) to its securities registration statement on February 9, 2023. The filing confirms the registration of securities under the same form as a prior submission, with updated administrative details.

2023-02-09 · 9999999995-23-000341

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received effectiveness for its filing on February 9, 2023. The current filing (POS AM) follows a previous similar submission with a different file number, indicating a revised or updated registration statement.

2023-02-09 · 9999999995-23-000342

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received effectiveness for its registration statement on February 9, 2023. The current filing (Accession No. 0001558370-23-000869) updates the previous submission (Accession No. 0001558370-23-000874) with revised file numbers, indicating an amended or updated registration statement.

2023-02-09 · 9999999995-23-000343

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows RW and marks the registration effective.

CytoDyn Inc. received effectiveness for its S-3 registration statement, allowing it to proceed with a securities offering. This follows a prior request to withdraw a similar registration in September 2022, indicating a reversal in the company's strategy or updated regulatory compliance.

2022-09-30 · 9999999995-22-002886

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows EFFECT and ends the active registration process.

CytoDyn Inc. has requested the withdrawal of its S-3 registration statement filed on March 3, 2021, as it no longer intends to pursue the contemplated public offering. The registration statement was never declared effective, and no securities were issued or sold under it.

2022-09-26 · 0001558370-22-014616

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

208,720,547 shares · Gross proceeds $0.00

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants to purchase common stock · Selling stockholders only · Use of proceeds Selling stockholders will receive all proceeds

CytoDyn Inc. is registering up to 208,720,547 shares of common stock for sale by selling stockholders, including shares from private sales in 2022, 2021, and warrant issuances related to settlements, severance, and surety bonds. The company will not receive proceeds from these sales, which are governed by registration rights. The shares are listed on OTCQB under 'CYDY,' with a closing price of $0.49 as of September 1, 2022.

2022-09-02 · 0001558370-22-014181

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its S-3 registration statement, confirming the SEC has declared the registration effective. The filing allows the company to offer up to 208,720,547 shares of common stock and underlying warrants held by selling stockholders. The shares include those from private sales, warrants, and settlements, with no proceeds going to the company. The stock is listed on the OTCQB under 'CYDY' with a closing price of $0.49 as of September 1, 2022.

2022-09-02 · 9999999995-22-002579

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. filed an S-3 form with the SEC, indicating the effectiveness of its securities offering on October 6, 2021. This follows a prior S-3 filing in January 2021, but no specific details about the offering's terms, proceeds, or purpose are provided in the text.

2021-10-06 · 9999999995-21-003797

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received effectiveness for its S-3 registration statement on January 22, 2021, following a previous effectiveness date of December 30, 2020. The filing relates to a shelf registration, allowing the company to offer securities in the future without immediate prospectus disclosure.

2021-01-22 · 9999999995-21-000252

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received SEC approval for its S-3 registration statement on December 30, 2020, following a prior effectiveness date in September 2020. The filing relates to potential securities offerings but contains no substantive content beyond standard SEC formatting and metadata.

2020-12-30 · 9999999995-20-003711

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. filed an S-3 registration statement, indicating a secondary offering of securities. The current filing became effective on September 25, 2020, following a prior effectiveness date in May 2020. No substantive details about the offering or company operations are provided in the text.

2020-09-25 · 9999999995-20-002582

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

CytoDyn Inc. received effectiveness for its S-3 registration statement, confirming the availability of 14,754,098 shares of common stock and 7,377,049 warrants to purchase shares. The offering, previously outlined in a 424B5 filing, includes terms tied to a License and Supply Agreement with Vyera Pharmaceuticals, granting exclusive rights to commercialize leronlimab (PRO 140) for HIV treatment. Phoenixus AG, Vyera's parent, and an entity linked to board member David F. Welch, are key investors. The filing emphasizes risks related to clinical trials, regulatory approvals, and market competition.

2020-05-11 · 9999999995-20-001113

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.31 · 14,754,098 shares · Gross proceeds $4,500,000

warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one-half of one warrant · Warrants to purchase 7,377,049 shares at $0.30 exercise price · Use of proceeds For general corporate purposes · Flags units, warrants

CytoDyn Inc. is offering 14,754,098 shares of common stock and 7,377,049 warrants to purchase shares, priced at $0.305 per share and half-warrant. The offering includes a Commercialization and License Agreement with Vyera Pharmaceuticals for leronlimab (PRO 140) and a Supply Agreement. Phoenixus AG, Vyera's parent, is purchasing 13,114,754 shares and warrants. The company also offers 1,639,344 shares and 819,672 warrants to David F. Welch, a board member. Proceeds of ~$4.5M will fund general corporate purposes.

2019-12-27 · 0001193125-19-325023

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.30 · 2,433,333 shares · Gross proceeds $730,000

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants to purchase up to 1,825,000 shares of common stock · Flags warrants

CytoDyn Inc. is offering 2,433,333 shares of common stock and warrants to purchase 1,825,000 shares at $0.30 per share/warrant, with proceeds estimated at $730,000 for clinical trials and general corporate purposes. The company focuses on leronlimab, a monoclonal antibody for HIV and other indications, with risks including clinical trial failures and regulatory hurdles. The offering follows a prior filing with similar terms but fewer shares and warrants.

2019-12-13 · 0001193125-19-314048

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.30 · 2,568,330 shares · Gross proceeds $770,499

Common Stock · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with three quarters of a warrant to purchase one share of common stock · Warrants to purchase up to 1,926,248 shares of common stock at an exercise price of $0.45 per share, exercisable for five years · Use of proceeds General corporate purposes

CytoDyn Inc. is offering 2,568,330 shares of common stock and warrants to purchase 1,926,248 shares at $0.30 per share/warrant, with proceeds estimated at $0.75 million after expenses. The offering supplements a prior prospectus, with shares and warrants to be issued separately. The company focuses on HIV treatments, including leronlimab (PRO 140), and expanding into cancer and immunological indications. The offering includes risk factors related to clinical trials, regulatory approvals, and financial stability.

2019-12-10 · 0001193125-19-309873

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.30 · 7,395,000 shares · Gross proceeds $2,218,500

Common Stock · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with three quarters of a warrant to purchase one share · Warrants exercisable for 5 years at $0.45 per share · Use of proceeds general corporate purposes · Flags units, warrants · Underwriters self-underwritten

CytoDyn Inc. is offering 7,395,000 shares of common stock and 5,546,250 warrants to purchase shares, with each share sold with three-quarters of a warrant at $0.30 per combined unit. The offering follows a prior filing in November 2019, with increased share and warrant quantities compared to the previous 2,353,333 shares and 1,765,000 warrants. Proceeds are estimated at $2.2 million, intended for clinical trials and corporate purposes. The company highlights risks related to clinical trial outcomes, regulatory approvals, and financial sustainability.

2019-11-20 · 0001193125-19-296192

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.30 · 2,353,333 shares · Gross proceeds $706,000

Common Stock · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold together with three quarters of a warrant to purchase one share of common stock · Warrants to purchase up to 1,765,000 shares of common stock exercisable at $0.45 per share for five years · Use of proceeds General corporate purposes

CytoDyn Inc. is offering 2,353,333 shares of common stock and warrants to purchase 1,765,000 shares at $0.30 per share/warrant, with warrants exercisable at $0.45. The offering aims to fund clinical trials and general corporate purposes. The company focuses on developing leronlimab, a monoclonal antibody for HIV and other indications, with risks including clinical trial failures and regulatory challenges.

2019-11-07 · 0001193125-19-286731

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.40 · 1,382,500 shares · Gross proceeds $553,000

Common Stock · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one half of a warrant to purchase one share · Warrants to purchase up to 691,250 shares of common stock at $0.45 per share, exercisable for 5 years · Use of proceeds Proceeds will be used for general corporate purposes · Flags units, warrants · Underwriters self-underwritten

CytoDyn Inc. is offering 1,382,500 shares of common stock and warrants to purchase 691,250 shares at $0.40 per share and half-warrant, with warrants exercisable at $0.45. The offering supplements a prior prospectus, with proceeds intended for clinical trials and corporate purposes. The company highlights risks related to clinical trial outcomes, regulatory approvals, and market acceptance of its HIV and cancer therapies.

2019-10-03 · 0001193125-19-261225

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

17,526,200 shares

Common Stock · Exchange OTCQB · Ticker CYDY · 7,526,200 warrants exercisable at $0.50 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes · Flags warrants

CytoDyn Inc. is registering 17,526,200 shares of common stock for resale by selling stockholders, including 10,000,000 shares from Series C Preferred Stock conversion and 7,526,200 shares from warrant exercises. The company will not receive proceeds from the sale but may get cash from warrant exercises. The filing relates to shares issued in private placements and warrant tender offers, with a focus on leronlimab, a monoclonal antibody for HIV and other indications.

2019-09-30 · 0001193125-19-258812

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its Form S-3 registration statement, confirming the availability of up to 17,526,200 shares of common stock for sale by selling stockholders. The shares include 10,000,000 from the conversion of Series C Preferred Stock and 7,526,200 from warrant exercises at $0.50 per share. The company will not receive proceeds from the sale but may receive cash from warrant exercises. The filing emphasizes risks related to clinical trials, regulatory approvals, and market competition.

2019-09-30 · 9999999995-19-002213

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.40 · 2,330,000 shares · Gross proceeds $932,000

half of a warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Common stock and half a warrant per share · Warrants to purchase up to 1,165,000 shares of common stock, exercisable at $0.45 for five years · Use of proceeds Proceeds to the company are $932,000 before expenses

CytoDyn Inc. is offering 2,330,000 shares of common stock and 1,165,000 warrants at $0.40 per share and half-warrant, with proceeds intended for clinical trials and general corporate purposes. The offering follows a prior filing in August 2019 for a larger share issuance. The company remains focused on developing leronlimab, a monoclonal antibody for HIV and other indications, while highlighting risks related to clinical trial outcomes and regulatory approvals.

2019-09-19 · 0001193125-19-249056

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Price $0.40 · 5,639,500 shares · Gross proceeds $2,255,800

half of a warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one half of a warrant · Warrants to purchase up to 2,819,750 shares of common stock at $0.45 per share · Use of proceeds Proceeds used for working capital and general corporate purposes · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 5,639,500 shares of common stock and warrants to purchase 2,819,750 shares at $0.40 per share and warrant, with proceeds targeting clinical trials and corporate purposes. This follows a prior resale offering (424B3) focused on existing shareholders. The company, a biotech firm developing HIV treatments, highlights risks including regulatory hurdles and clinical trial outcomes.

2019-08-29 · 0001193125-19-233115

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

101,909,672 shares

Common · Ticker CYDY · Warrants exercisable at $0.50 to $0.75 per share, expiring five years from issuance · Selling stockholders only · Use of proceeds Proceeds will be received by the selling shareholders, with no proceeds to the company

CytoDyn Inc.'s 424B3 filing supplements its February 2019 prospectus to reflect transfers of securities among selling shareholders, updating ownership figures in the selling shareholder table. The filing emphasizes that the prospectus and supplements contain forward-looking statements with risks, including clinical trial outcomes, regulatory approvals, and market competition. The company remains focused on developing leronlimab as an HIV treatment.

2019-07-15 · 0001193125-19-194092

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.50 · 2,201,000 shares · Gross proceeds $1,100,500

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants to purchase up to 1,100,500 shares of common stock, exercisable at $0.50 per share for five years · Use of proceeds To cover placement agent commissions and expenses · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 2,201,000 shares of common stock and 1,100,500 warrants at $0.50 per share/warrant, with net proceeds estimated at $1.0 million. The offering mirrors prior terms, including the placement agent (Paulson Investment Company, LLC) and use of proceeds for clinical trials and corporate purposes. The company emphasizes risks related to clinical trial outcomes, regulatory approval, and market viability for its HIV and oncology therapies.

2019-04-17 · 0001193125-19-108077

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.50 · 8,730,000 shares · Gross proceeds $4,365,000

half of a warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold together with one half of a warrant to purchase one share of common stock · Warrants to purchase up to 4,365,000 shares of common stock exercisable at $0.50 per share for five years · Use of proceeds General corporate purposes

CytoDyn Inc. is offering 8,730,000 shares of common stock and warrants to purchase 4,365,000 shares at $0.50 per combined unit. The offering, registered under a prospectus supplement, includes details on pricing, use of proceeds, and the role of Paulson Investment Company, LLC as the placement agent. The company intends to use net proceeds for clinical trials and general corporate purposes.

2019-04-05 · 0001193125-19-098476

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

101,909,672 shares · Gross proceeds $0.00

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants exercisable at $0.75 and $0.50 per share · Selling stockholders only · Use of proceeds No proceeds to the company; proceeds from warrant exercises

CytoDyn Inc. is offering up to 101,909,672 shares of common stock from selling stockholders, including shares from the ProstaGene acquisition, private placements, and warrants. The company does not receive proceeds from the sale but will receive cash from warrant exercises. The shares are listed on OTCQB under 'CYDY'.

2019-02-14 · 0001193125-19-039585

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its S-3 registration statement, allowing the sale of up to 101,909,672 shares of common stock by selling stockholders. The shares include those from an acquisition, private placements, and warrant exercises. The company will not receive proceeds from the sale but may receive cash from warrant exercises. The stock is traded on OTCQB under 'CYDY.'

2019-02-14 · 9999999995-19-000265

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.50 · 1,320,000 shares · Gross proceeds $660,000

half of a warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one half of a warrant · Warrants to purchase 660,000 shares of common stock at $0.50 per share · Use of proceeds Proceeds to be used for general corporate purposes · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 1,320,000 shares of common stock and 660,000 warrants at $0.50 per combined share and half-warrant. The offering follows a previous 424B5 filing for 3,522,000 shares and 1,761,000 warrants. Proceeds, after commissions, are estimated at $0.6 million for clinical trials and general corporate purposes. The company focuses on HIV treatment with leronlimab, a CCR5 inhibitor, and expanding into cancer and immunological indications. Risks include clinical trial failures, regulatory hurdles, and reliance on a single product candidate.

2019-02-13 · 0001193125-19-036928

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.50 · 3,522,000 shares · Gross proceeds $1,761,000

half of a warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold together with one half of a warrant to purchase one share of common stock for the combined purchase price of $0.50 · Warrants to purchase up to 1,761,000 shares of common stock exercisable at $0.50 per share for five years · Use of proceeds General corporate purposes

CytoDyn Inc. is offering 3,522,000 shares of common stock and 1,761,000 warrants at $0.50 per share and warrant, with net proceeds estimated at $1.6 million for clinical trials and general corporate purposes. The offering mirrors prior terms, including the placement agent (Paulson Investment Company, LLC) and structure of separate stock and warrant issuance.

2019-02-08 · 0001193125-19-031455

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.50 · 5,886,480 shares · Gross proceeds $2,943,240

Common Stock · Exchange OTCQB · Ticker CYDY · Common Stock and Warrants · Warrants to purchase up to 2,943,240 shares of common stock exercisable at $0.50 per share for 5 years · Use of proceeds Use of proceeds not specified

CytoDyn Inc. is offering 5,886,480 shares of common stock and warrants to purchase 2,943,240 shares at $0.50 per combined unit. The proceeds, estimated at $2.6 million, will fund clinical trials for leronlimab, an HIV treatment, and general corporate purposes. The company is a biotech focused on monoclonal antibodies for HIV, cancer, and immunological conditions, with leronlimab showing potential as a CCR5 inhibitor. The offering follows a prior registration statement effective in November 2018.

2019-01-31 · 0001193125-19-023155

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 425 and marks the registration effective.

CytoDyn Inc. announced the anticipated closing of its acquisition of ProstaGene, LLC, scheduled for December 7, 2018. A registration statement on Form S-4, including a preliminary prospectus, was filed with the SEC for the transaction. Investors are advised to review the Form S-4 and other documents for critical details.

2018-11-28 · 9999999995-18-002985

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. received effectiveness for a Post-Effective Amendment (POS AM) to its securities registration on November 28, 2018. The filing relates to a prior registration statement (File Number 333-223195) and appears to be a routine update or correction to the initial registration.

2018-11-28 · 9999999995-18-002986

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for a post-effective amendment (POS AM) on November 28, 2018. The filing relates to a securities registration statement, with a new file number (333-223563) compared to a prior filing (333-223195). No substantive details about the offering or changes are provided in the text.

2018-11-28 · 9999999995-18-002987

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

CytoDyn Inc. announced on November 5, 2018, that its acquisition of ProstaGene, LLC is expected to close by December 7, 2018. A notice to security holders is included as Exhibit 99.1. The filing emphasizes that the ProstaGene transaction involves a Form S-4 registration statement, urging investors to review relevant documents filed with the SEC. The company also reiterated forward-looking statements regarding clinical trials and regulatory approvals, alongside material risks.

2018-11-05 · 0001193125-18-318490

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B5 in the pre-IPO sequence.

CytoDyn Inc. filed an 8-K/A to amend its prior 8-K, correcting the cover page by marking the 'Written communications pursuant to Rule 425' box and adding a required legend about the securities offering. The amendment does not alter other information from the original filing, which related to a securities offering and merger-related disclosures.

2018-08-31 · 0001193125-18-265068

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.50 · 1,970,000 shares · Gross proceeds $985,000

warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one warrant to purchase one share of common stock for a combined purchase price of $0.50 · Warrants to purchase up to 1,970,000 shares of common stock, exercisable for five years at $0.75 per share · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 1,970,000 shares of common stock and warrants to purchase up to 1,970,000 shares at $0.50 per combined unit. The offering follows a previous 424B5 filing for 4,640,000 shares, with reduced share volume and adjusted proceeds. The company plans to use net proceeds for clinical trials and general corporate purposes, emphasizing its HIV treatment candidate PRO 140. The offering includes risk disclosures about clinical trial uncertainties, regulatory challenges, and market competition.

2018-06-15 · 0001193125-18-193657

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.50 · 4,640,000 shares · Gross proceeds $2,320,000

warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one warrant to purchase one share of common stock · Warrants exercisable at $0.75 per share for five years · Use of proceeds for general corporate purposes

CytoDyn Inc. is offering 4,640,000 shares of common stock and warrants to purchase up to 4,640,000 shares at a combined price of $0.50 per share and warrant. The offering supplements a previously effective registration statement (S-3) and includes details on use of proceeds, placement agent terms, and risk factors related to clinical trials and regulatory approval. The company, a biotech focused on HIV treatments, emphasizes PRO 140's potential as a novel therapy with lower toxicity compared to existing options.

2018-05-22 · 0001193125-18-170195

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B2 and confirms the priced prospectus.

79,752,367 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants with exercise prices ranging from $0.55 to $1.35, subject to a tender offer at $0.50 · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, no proceeds to the issuer from share sales

CytoDyn Inc. is registering 79,752,367 shares of common stock for resale by selling stockholders, sourced from multiple private placements and warrant exercises. The shares include those from the February 2018 Placement, Make-Whole Transaction, Convertible Notes Transaction, and April 2016 Placement. The company will not receive proceeds from the sale but will collect cash from exercised warrants. The offering details the structure of warrant tender offers and expiration terms.

2018-03-23 · 0001193125-18-094145

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed an S-3 registration statement for the sale of up to 79,752,367 shares of common stock by selling stockholders, including shares from private placements, warrant exercises, and convertible notes. The filing became effective on March 23, 2018, with no proceeds to the company, only cash from warrant exercises. The company's stock is quoted on OTCQB under 'CYDY.'

2018-03-23 · 9999999995-18-000667

424B2 filed

Prospectus supplement

Prospectus supplement that can carry timing details without itself confirming imminent trading.

Follows EFFECT in the pre-IPO sequence.

Price $200,000,000 · Gross proceeds $200,000,000

Common Stock, Preferred Stock, Warrants, Debt Securities, Units · Exchange OTCQB · Ticker CYDY

CytoDyn Inc. is offering up to $200 million in securities, including common stock, preferred stock, debt, warrants, and units, under a prospectus supplement. The filing outlines potential future offerings and emphasizes risks related to clinical trials, regulatory approvals, and financial sustainability. The company focuses on developing PRO 140, a monoclonal antibody for HIV treatment, with risks including reliance on trial outcomes and market competition.

2018-03-09 · 0001193125-18-077275

424B2 filed

Prospectus supplement

Prospectus supplement that can carry timing details without itself confirming imminent trading.

Follows 424B2 in the pre-IPO sequence.

25,667,055 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants to purchase shares at $1.00 and $0.75 per share, issued on various dates, expiring five years after issuance

CytoDyn Inc. is registering 25,667,055 shares of common stock issuable upon exercise of outstanding warrants, which have exercise prices of $1.00 or $0.75 per share. The warrants expire five years from their issuance dates. The company emphasizes the risks associated with its clinical-stage biotechnology operations, including reliance on the success of its PRO 140 HIV treatment candidate and regulatory approvals. The securities are quoted on the OTCQB under the symbol CYDY.

2018-03-09 · 0001193125-18-077448

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

CytoDyn Inc. issued a Notice of Effectiveness for its S-3 registration statement, confirming the availability of 12,062,728 shares of common stock and warrants to purchase 7,718,010 shares at $0.50 per share. The offering was structured to satisfy $6.0 million in convertible promissory note obligations, with proceeds used to settle debt. The company's common stock is quoted on the OTCQB under 'CYDY,' and the placement agent was Paulson Investment Company, LLC.

2018-03-07 · 9999999995-18-000551

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.50 · 12,062,728 shares · Gross proceeds $6,031,364

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants exercisable at $0.75 per share for five years · Use of proceeds To satisfy payment obligations pursuant to convertible promissory notes

CytoDyn Inc. is offering 12,062,728 shares of common stock and 7,718,010 warrants to purchase shares, priced at $0.50 per share and related warrants. The offering aims to satisfy $6.0 million in payment obligations from matured convertible promissory notes, with proceeds exclusively allocated to debt settlement. The previous filing on 2018-01-23 offered a smaller scale of 3,071,014 shares and warrants, without specifying debt repayment as the primary use of proceeds.

2018-01-31 · 0001193125-18-027515

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.50 · 3,071,014 shares · Gross proceeds $1,535,507

warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one warrant to purchase one share · Warrants exercisable at $0.75 per share for 5 years · Use of proceeds to pay placement agent fees and expenses · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 3,071,014 shares of common stock and warrants to purchase up to 3,071,014 shares at a combined price of $0.50 per share and warrant. The offering aims to raise approximately $1.4 million for clinical trials and general corporate purposes. The company, a clinical-stage biotechnology firm focused on HIV treatments, highlights PRO 140 as a potential therapeutic with fewer side effects compared to existing HIV drugs. The offering follows a previous 424B5 filing in October 2017, which offered fewer shares and warrants at a higher price.

2018-01-23 · 0001193125-18-016751

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.65 · 1,880,765 shares · Gross proceeds $1,222,500

Common · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one half of a warrant to purchase one share · Warrants exercisable at $0.75 per share for five years · Use of proceeds Proceeds to be used for general corporate purposes and offering expenses · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 1,880,765 shares of common stock and 940,380 warrants at a combined price of $0.65 per share and half-warrant, down from the previous offering's $0.75. The offering includes a reduced number of shares and warrants compared to the prior filing, with net proceeds estimated at $1.11 million. The company plans to use proceeds for clinical trials and general corporate purposes, including debt reduction. The placement agent, Paulson Investment Company, LLC, receives lower commissions, and warrant exercise prices have decreased from $1.00 to $0.75.

2017-10-11 · 0001193125-17-307551

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.75 · 3,336,331 shares · Gross proceeds $2,322,049

Common Stock · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with one half of a warrant to purchase one share · Warrants to purchase up to 1,668,103 shares of common stock at $1.00 per share exercisable for five years · Use of proceeds To pay placement agent commissions and for general corporate purposes · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 3,336,331 shares of common stock and warrants to purchase 1,668,103 shares at $0.75 per combined share and warrant. The offering aims to raise approximately $2.24 million for clinical trials and general corporate purposes. The company's lead product, PRO 140, is a monoclonal antibody for HIV treatment, with risks tied to clinical trial outcomes and regulatory approvals.

2017-09-08 · 0001193125-17-279792

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.75 · 5,670,661 shares · Gross proceeds $4,253,002

common · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold together with one half of a warrant · Warrants to purchase up to 2,835,323 shares of common stock exercisable for five years at $1.00 per share · Flags units, warrants · Underwriters Paulson Investment Company, LLC

CytoDyn Inc. is offering 5,670,661 shares of common stock and 2,835,323 warrants at $0.75 per share/warrant, with net proceeds estimated at $3.8 million for clinical trials and general corporate purposes. The offering follows a previous 424B5 filing in January 2017 for a smaller share/warrant amount. The company, a clinical-stage biotech focused on HIV treatments, highlights its PRO 140 antibody as a potential alternative to existing therapies, though risks include clinical trial failures and regulatory hurdles.

2017-02-28 · 0001193125-17-060264

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.75 · 1,534,999 shares · Gross proceeds $1,151,251

half of a warrant to purchase one share · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold together with one half of a warrant to purchase one share of common stock for the combined purchase price of $0.75. · Warrants to purchase up to 767,498 shares of common stock exercisable for five years at $1.00 per share.

CytoDyn Inc. is offering 1,534,999 shares of common stock and 767,498 warrants to purchase shares, with each share sold with a half-warrant at $0.75. The offering aims to raise ~$1.0 million for clinical trials and general corporate purposes. The company, focused on HIV treatment with PRO 140, highlights its entry inhibitor mechanism and potential advantages over existing therapies. The placement agent, Paulson Investment Company, LLC, receives commissions and additional warrants.

2017-01-31 · 0001193125-17-024614

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.75 · 4,000,000 shares · Gross proceeds $3,000,000

Common Stock · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with a warrant to purchase one-half of a share of common stock · Warrants to purchase up to 2,000,000 shares of common stock exercisable at $1.00 per share for five years · Use of proceeds Proceeds to the company are $3,000,000 before expenses · Flags units

CytoDyn Inc. is offering up to 4,000,000 shares of common stock and 2,000,000 warrants to purchase shares, priced at $0.75 per combined share/warrant. The offering aims to fund clinical trials and general corporate purposes, with net proceeds estimated at $3.0 million. The company, a clinical-stage biotech focused on HIV treatments, highlights its lead candidate PRO 140 as a potential alternative to existing therapies, though risks related to clinical trials and market acceptance are emphasized.

2016-12-12 · 0001193125-16-790791

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

44,786,050 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants exercisable at prices ranging from $0.50 to $1.02 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes

CytoDyn Inc. is offering up to 44,786,050 shares of common stock from warrant exercises, primarily from previous private placements between 2013 and 2016. The company does not receive proceeds from the sale of these shares but will receive the exercise price for warrants exercised in cash. The offering includes shares from multiple placements, such as the January 2016, August 2015, and July 2015 placements, as well as warrants issued to placement agents and consultants.

2016-10-21 · 0001193125-16-743637

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed an S-3 registration statement for the sale of up to 44,786,050 shares of common stock through warrant exercises by selling stockholders. The shares relate to multiple private placements and financings between 2013 and 2016, with the company not receiving proceeds from the sales but benefiting from warrant exercise prices. The filing emphasizes risks associated with clinical trials, regulatory approvals, and market competition for its HIV treatment candidate PRO 140.

2016-10-21 · 9999999995-16-006050

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.75 · 13,333,334 shares · Gross proceeds $10,000,000

Common Stock · Exchange OTCQB · Ticker CYDY · Each share of common stock is sold with a warrant to purchase one-half of a share · Warrants to purchase up to 6,666,667 shares of common stock, exercisable for five years at $1.00 per share · Use of proceeds For general corporate purposes

CytoDyn Inc. is offering 13,333,334 shares of common stock and warrants to purchase 6,666,667 shares at $0.75 per combined unit. The offering is led by H.C. Wainwright & Co., LLC as the exclusive placement agent, with net proceeds estimated at $9.2 million for clinical trials and general corporate use. The company, a biotechnology firm focused on HIV treatments, highlights its lead product PRO 140 as a potential alternative to existing therapies, though risks include clinical trial failures and regulatory hurdles.

2016-09-13 · 0001193125-16-707923

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its S-3 registration statement, confirming the SEC's acceptance of its securities registration. The filing incorporates by reference updates including a quarterly report (10-Q), current report (8-K), and proxy statement (14A) from early 2016, which supplement the prospectus dated February 17, 2016. The effectiveness date is September 9, 2016.

2016-09-09 · 9999999995-16-005659

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

17,861,210 shares

Common

CytoDyn Inc. filed a prospectus supplement (424B3) updating its earlier prospectus with recent financial reports and regulatory filings, including quarterly reports (10-Q) and current reports (8-K). The supplement incorporates documents up to April 13, 2016, and highlights the company's focus on HIV treatment development, particularly its lead candidate PRO 140. The filing also references ongoing clinical trials and financial updates, emphasizing risks related to regulatory approvals, financial stability, and market competition.

2016-04-13 · 0001193125-16-540022

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

30,754,131 shares

common · Ticker CYDY

The current filing updates the prospectus for CytoDyn Inc. with recent financial statements and other regulatory filings, including a Q4 2015 10-Q and multiple 8-K reports. It reflects the company's ongoing financial challenges, including significant operating losses and negative equity, while supplementing the prospectus with updated disclosures.

2016-04-13 · 0001193125-16-540024

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

53,974,076 shares

Common Stock · Exchange OTCQB · Ticker CYDY

CytoDyn Inc.'s April 13, 2016 424B3 filing updates its prospectus with recent financial reports, including a Q1 2016 10-Q, multiple 8-K filings, and a proxy statement. The filing highlights the company's focus on developing PRO 140, an HIV entry inhibitor, while disclosing significant operating losses and liquidity challenges. The prospectus supplement incorporates updated financial data and regulatory disclosures.

2016-04-13 · 0001193125-16-540032

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

53,974,076 shares · Gross proceeds $0.00

common · Exchange OTCQB · Ticker CYDY · Warrants issued in private placements and to placement agents and consultants with exercise prices between $0.75 and $1.02 · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, no proceeds to the company

CytoDyn Inc. is registering 53,974,076 shares of common stock for resale by selling shareholders, including shares from private placements and warrants issued in 2015-2016. The company will not receive proceeds from share sales but may collect cash from warrant exercises. The shares are traded on OTCQB under 'CYDY', with a recent closing price of $1.09. The filing highlights risks related to clinical trials, regulatory approvals, and financial uncertainties.

2016-02-18 · 0001193125-16-467380

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its S-1 registration statement on February 17, 2016, allowing the company to offer up to 53,974,076 shares of common stock for resale by selling shareholders. The shares include those from private placements, warrants, and consultant warrants, with no proceeds going to the company directly but potential cash proceeds from warrant exercises. The filing follows the initial S-1 submission on February 2, 2016, and confirms the registration's effectiveness for public offering.

2016-02-17 · 9999999995-16-003794

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $1.08 · 53,974,076 shares · Gross proceeds $58,022,132

Common Stock, par value $0.001 per share · Exchange OTCQB · Ticker CYDY · Warrants exercisable at $0.75, $1.02, or $0.92 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, no proceeds to the company · Flags warrants

CytoDyn Inc. is a clinical-stage biotechnology company focused on developing PRO 140, a humanized monoclonal antibody for HIV treatment. This S-1 filing registers 53,974,076 shares of common stock for resale by selling shareholders, including shares from private placements, warrants, and consultant warrants. The company does not receive proceeds from share sales but may receive cash from warrant exercises. PRO 140 is in Phase 2b/3 trials, with potential regulatory approval as an adjunct therapy.

2016-02-03 · 0001193125-16-448171

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

17,861,210 shares

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants exercisable at $0.75 per share issued in July and August 2015 placements · Selling stockholders only · Use of proceeds Proceeds from warrant exercises used for working capital

CytoDyn Inc. is registering up to 17,861,210 shares of common stock for resale by selling shareholders, including shares from private placements in August 2015, July 2015, and May 2015, along with warrants and incremental shares from an exchange offer. The company will not receive proceeds from share sales but may receive cash from warrant exercises. The shares are being offered under a prospectus highlighting risks related to clinical trials, regulatory approval, and financial viability.

2015-10-05 · 0001193125-15-337599

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

CytoDyn Inc. filed an S-1 registration statement for the resale of up to 17,861,210 shares of common stock by selling shareholders, including shares from August 2015, July 2015, and May 2015 private placements, along with warrants. The company will not receive proceeds from share sales but will receive cash from warrant exercises. The filing confirms the effectiveness of the registration, allowing the resale of these securities.

2015-10-05 · 9999999995-15-002662

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.72 · 17,861,210 shares · Gross proceeds $12,901,867

Common Stock, par value $0.001 per share · Exchange OTCQB · Ticker CYDY · Warrants exercisable at $0.75 per share, with 449,999 and 4,892,791 shares issuable upon exercise, plus 1,272,131 from placement agents · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for working capital and general corporate purposes

CytoDyn Inc. filed an S-1/A registration statement to amend its initial S-1 filing for an IPO, focusing on reselling shares from recent private placements. The filing includes shares from the August 2015, July 2015, and May 2015 placements, with adjustments to the number of incremental shares from the May 2015 Placement. The company, a biotechnology firm developing HIV treatments like PRO 140, emphasizes its clinical-stage pipeline and risks related to regulatory approval and financial stability.

2015-10-01 · 0001193125-15-335514

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Price $0.72 · 18,044,568 shares · Gross proceeds $12,901,867

Common Stock, par value $0.001 per share · Exchange OTCQB · Ticker CYDY · Warrants exercisable at $0.75 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises for cash

CytoDyn Inc. is registering up to 18,044,568 shares of common stock for resale by selling shareholders, including shares from recent private placements in August 2015, July 2015, and incremental shares from a May 2015 placement. The filing details warrants exercisable at $0.75 per share and outlines the company's focus on HIV treatments, including its lead candidate PRO 140. The company will not receive proceeds from share sales but will collect cash from exercised warrants.

2015-09-11 · 0001193125-15-318527

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

30,754,131 shares · Gross proceeds $0.00

common stock of CytoDyn Inc. · Exchange OTCQB · Ticker CYDY · Warrants issued in private placements, bridge financing, and conversion inducements with exercise prices ranging from $0.50 to $1.00 · Selling stockholders only · Use of proceeds Cash proceeds from warrant exercises

CytoDyn Inc. is registering 30,754,131 shares of common stock for resale by selling shareholders, including shares from warrant exercises, convertible note conversions, and private placement transactions. The company will not receive proceeds from share sales but may receive cash from warrant exercises. The shares are traded on OTCQB under 'CYDY'. The filing supplements prior registration statements with details on share sources and distribution methods.

2015-09-03 · 0001193125-15-310834

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.98 · 30,754,131 shares

Common Stock, no par value · Exchange OTCQB · Ticker CYDY · Warrants exercisable at $0.50-$1.00 per share issued in private placements, bridge financing, and note conversions · Selling stockholders only · Use of proceeds Selling stockholders are offering shares; the company will receive cash from warrant exercises

CytoDyn Inc. is a biotechnology company focused on developing humanized monoclonal antibodies for HIV treatment, particularly PRO 140, an entry inhibitor. This S-1/A filing relates to the resale of up to 30,754,131 shares of common stock by selling shareholders, including shares from private placements, warrant exercises, and promissory note conversions. The company does not receive proceeds from the sale but may receive cash from warrant exercises. The filing highlights risks related to clinical trials, regulatory approval, and financial sustainability.

2015-09-02 · 0001193125-15-309690

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its registration statement on September 2, 2015, indicating the SEC has accepted the filing. The registration covers up to 30,754,131 shares of common stock for resale by selling shareholders, including shares from warrant exercises, promissory note conversions, and private placement transactions. The filing emphasizes that the company will not receive proceeds from the sale of these shares but may receive cash from warrant exercises.

2015-09-02 · 9999999995-15-002423

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

CytoDyn Inc. filed a Notice of Effectiveness for its S-1 registration statement on September 2, 2015, indicating the SEC has declared the filing effective. The company, a biotechnology firm focused on HIV treatment, likely prepared for its initial public offering (IPO) during this period. The previous filing was a Post-Effective Amendment (POS AM) for a different registration statement.

2015-09-02 · 9999999995-15-002427

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.98 · 30,754,131 shares · Gross proceeds $30,139,048

Common Stock · Exchange OTCQB · Ticker CYDY · Warrants exercisable at various prices, including $0.50, $0.75, and $1.00 per share · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be used for general corporate purposes

CytoDyn Inc. is registering 30,754,131 shares of common stock for resale by selling shareholders, including shares from warrant exercises, promissory note conversions, and private placement transactions. The filing amends the previous S-1 to delay the effective date and includes details on the company's clinical-stage HIV therapies, including PRO 140, a monoclonal antibody entry inhibitor. The company seeks shareholder approval to reincorporate in Delaware and faces risks related to regulatory approval, financial stability, and market competition.

2015-08-20 · 0001193125-15-296581

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

First tracked pre-IPO filing for this issuer.

Price $0.98 · 30,754,131 shares

no par value · Exchange OTCQB · Ticker CYDY · Warrants exercisable at various prices, including $0.50, $0.75, and $1.00 per share · Selling stockholders only · Use of proceeds Cash proceeds from warrant exercises

CytoDyn Inc. is a biotechnology company focused on developing humanized monoclonal antibodies for HIV treatment and prevention. This S-1 filing registers 30,754,131 shares of common stock for resale by selling shareholders, including shares from warrant exercises, convertible notes, and private placement transactions. The company's lead product, PRO 140, is an HIV entry inhibitor, with additional platform technologies targeting HIV and Feline Immunodeficiency Virus. The offering includes shares from various financings, such as bridge notes, private placements, and inducements for warrant exercises.

2015-06-08 · 0001193125-15-216414

CytoDyn Inc.

Filing Timeline

9 comparable deals

Recent News